Kelly Curtin
Managing Director
London Office | kelly.curtin@torreya.com | +44 (0) 207 451 4564
Kelly Curtin, a Managing Director on Torreya’s European team, advises clients on strategic transactions across the life sciences industry. She has over 20 years of experience in investment banking, primarily in the healthcare industry.
Her experience includes strategic transactions across a wide spectrum of the life sciences, including biotechnology, pharma, specialty pharma, generics, healthcare services and medical devices. Kelly has led M&A transactions for public and private companies, licensing transactions and divestments as well as executed a range of equity and debt financings.
Recent transactions on which Kelly has worked include Orion’s global collaboration for the development and commercialization of ODM-208 with Merck, Medigene’s global multi-target collaboration with BioNTech to discover and develop TCR immunotherapies, Calliditas’ out-license of its specialty therapy for IgA Nephropathy in Europe to Stada, and the licensing of Mereo’s Navicixizumab to Oncologie.
Before joining Torreya in 2014, Kelly was a Director in Credit Suisse’s Mergers & Acquisitions group in Chicago and London.
Kelly holds a B.A. in Law, Jurisprudence and Social Thought from Amherst College.
Selected Transactions
|
| Global collaboration for the development and commercialization of ODM-208 with |
|
|
$290 million upfront
July 2022
|
|
| Sale of U.S. manufacturing facility and long-term supply agreement with |
|
|
$44.5 million
April 2022
|
|
| Global multi-target collaboration to discover and develop TCR immunotherapies; acquisition of PRAME TCR |
|
|
€26 million upfront
February 2022
|
|
| Licensing of Budesolv in China to |
|
|
October 2021
|
|
| Out-license of specialty therapy for IgA Nephropathy in Europe to |
|
|
Up to €97.5 million
plus royalties July 2021
|
|
| Recommended cash acquisition by |
|
|
£48.3 million
November 2022
|
|
| License of Galinpepimut-S in Greater China by |
|
|
Up to $202 million with $7.5 million upfront
December 2020
|
|
| License of Navicixizumab to |
|
|
Up to $306 million
January 2020
|
|
| Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC |
|
|
Up to $19 million
November 2018
|
|
| Licensing of ex European rights for LYS-SAF302 to |
|
|
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
|
|
| Licensing agreement for Feraccru® in Europe, Australia and New Zealand with |
|
|
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
|
|
|
| Acquisition of |
|
|
Up to $30 million
December 2015
|